Skip to main content
TMCI
NASDAQ Industrial Applications And Services

Treace 10-Q: Q3 Revenue Down 4% to $48.3M, Cash Burn Narrows to $0.7M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$4.355
Mkt Cap
$271.844M
52W Low
$1.17
52W High
$6.55
52W Position info
272% above low
Off High info
34% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

TMCI has more than doubled off its 52-week low of $1.17.

Summary

Treace's Q3 10-Q confirms the $48.3 million revenue and narrowed $12.6 million net loss already reported, and details a balance sheet with $39.8 million of cash and securities against $60.0 million of term debt, plus nine-month operating cash use of just $0.7 million.


Key Events · Earnings and Guidance · TMCI

  • Q3 Revenue Falls 4% to $48.3M

    Revenue was $48.3 million versus $50.2 million a year earlier, with a $5.1 million drop in stocking-distributor sales and a mix shift to lower-priced minimally invasive kits; nine-month revenue fell 6.2% to $140.8 million.

  • Net Loss Narrows 23%

    Net loss was $12.6 million, or $0.19 per share, versus $16.3 million, or $0.26, a year earlier, as sales and marketing expense fell 13.7% to $29.7 million.

  • Cash Burn Nearly Eliminated

    Nine-month operating cash use was $0.7 million versus $7.9 million in 2025, aided by $21.4 million of non-cash stock compensation and a $3.5 million depreciation reduction from extending surgical-instrument useful lives to five years.

  • Liquidity Thin Against $60M Term Loan

    At September 30, 2026 the company held $7.8 million of cash and $32.0 million of marketable securities against $60.0 million of term-loan principal; management says resources fund operations for at least twelve months.


Analysis · TMCI · Industrial Applications And Services

The headline numbers match this morning's 8-K, but the full 10-Q reveals how thin the balance sheet has become: $7.8 million of cash plus $32.0 million of marketable securities against $60.0 million of term-loan principal, with $295.4 million of accumulated deficit and equity down to $61.6 million from $87.3 million at year-end. The offset is that cash burn has nearly stopped — nine-month operating cash use fell to $0.7 million from $7.9 million — helped by a $3.5 million depreciation reduction from extending surgical-instrument useful lives to five years and by $21.4 million of non-cash stock compensation. Management states existing cash, securities and available borrowings fund operations for at least twelve months, but the $55.0 million of remaining term-loan tranches are tied to revenue targets the company is not currently hitting, so the revolver and equity remain the realistic backstops.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TMCI was trading at $4.36 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $271.8M. The 52-week trading range was $1.17 to $6.55. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TMCI - Latest Insights

TMCI
Nov 06, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.25
Real-time Price: $4.31 info
Change: +$0.060 (+1%) info
Market Cap: $282.562M info
TMCI
Nov 06, 2026, 7:05 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $4.36
Real-time Price: $4.31 info
Change: -$0.045 (-1%) info
Market Cap: $282.562M info
TMCI
Sep 17, 2026, 5:16 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.69
Real-time Price: $4.31 info
Change: -$0.380 (-8%) info
Market Cap: $282.562M info
TMCI
Aug 08, 2026, 3:13 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $4.70
Real-time Price: $4.31 info
Change: -$0.390 (-8%) info
Market Cap: $282.562M info
TMCI
Aug 07, 2026, 7:42 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $4.75
Real-time Price: $4.31 info
Change: -$0.440 (-9%) info
Market Cap: $282.562M info